Phesgo Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing diagnosis of her2-positive breast cancer, advancements in monoclonal antibody development, expansion of oncology infusion centers, improved survival outcomes with targeted therapy, growth in biologic drug approvals.

The growth in the forecast period can be attributed to expansion of home-based oncology treatment models, rising investments in combination biologic therapies, increasing adoption of subcutaneous drug delivery, advancements in formulation stability technologies, growing demand for efficient cancer treatment protocols. Major trends in the forecast period include increasing adoption of fixed-dose combination therapies, rising preference for subcutaneous oncology treatments, expansion of her2-positive breast cancer therapies, growing focus on patient convenience and compliance, enhanced biologic formulation technologies.

The rising incidence of breast cancer is expected to drive the growth of the Phesgo market in the coming years. Breast cancer, which originates in the cells of the breast - most commonly in the milk ducts or lobules - can metastasize to other parts of the body. Factors contributing to the increasing incidence include aging populations, genetic predisposition, lifestyle changes, environmental exposures, and hormonal influences. Phesgo provides a convenient, fixed-dose combination of pertuzumab and trastuzumab, two targeted therapies that work together to inhibit the HER2 protein, which is responsible for tumor growth and progression. This combination reduces administration time and enhances the overall treatment experience. For example, according to the American Cancer Society, new breast cancer cases in the United States increased from 300,590 in 2023 to 313,510 in 2024. Therefore, the rising incidence of breast cancer is driving Phesgo market growth.

The growing demand for personalized medicine is also expected to propel the Phesgo market forward. Personalized medicine tailors treatment to an individual’s genetic profile, lifestyle, and environment to provide more effective therapies. Advances in genomics have enabled targeted treatments that improve patient outcomes and minimize side effects. Phesgo supports personalized care by combining pertuzumab and trastuzumab into a single subcutaneous injection, specifically targeting the HER2 protein in HER2-positive breast cancer patients and streamlining treatment delivery. For instance, in February 2024, the Personalized Medicine Coalition reported that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Among these, seven were cancer drugs and three targeted other diseases. This trend highlights the growing focus on individualized treatment, which is driving Phesgo adoption.

Key companies in the Phesgo market are prioritizing the development of innovative therapies, such as monoclonal antibody combination treatments, to improve efficacy and patient outcomes in oncology. Monoclonal antibody combination therapy uses two or more antibodies to target different disease pathways, often enhancing treatment effectiveness and overcoming resistance. For example, in November 2023, Chugai Pharmaceutical Co. Ltd., a Japan-based company, launched Phesgo for subcutaneous injection. This therapy combines pertuzumab and trastuzumab with hyaluronidase alfa to treat HER2-positive breast cancer and advanced HER2-positive colorectal cancer, offering a more convenient alternative to intravenous infusion and improving patient adherence and treatment experience.

Major companies operating in the phesgo market are F. Hoffmann-La Roche AG, Chugai Pharmaceutical Co. Ltd.

North America was the largest region in the phesgo market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the phesgo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the phesgo market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the phesgo market by increasing costs of imported biologic raw materials, formulation excipients, delivery devices, and sterile packaging used in combination oncology drugs. Manufacturing hubs in North America and Europe are most affected due to dependence on cross-border biologics supply chains, while Asia-Pacific faces increased distribution and export costs. These tariffs are elevating production expenses and impacting therapy pricing. However, they are also driving investments in localized biologics manufacturing, regional formulation capabilities, and long-term supply chain optimization for oncology treatments.

The phesgo market research report is one of a series of new reports that provides phesgo market statistics, including phesgo industry global market size, regional shares, competitors with a phesgo market share, detailed phesgo market segments, market trends and opportunities, and any further data you may need to thrive in the phesgo industry. This phesgo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Phesgo is a fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase, formulated for subcutaneous injection. It is used to treat HER2-positive breast cancer in both early and metastatic stages, often alongside chemotherapy.

The primary indications for Phesgo include early breast cancer and metastatic breast cancer. Early breast cancer, diagnosed at stages 0, I, or II, is treated with Phesgo to lower the risk of recurrence in HER2-positive patients. Phesgo is available in subcutaneous injection and intravenous infusion formulations. It is distributed through direct sales, online pharmacies, and wholesale distributors, and is used by end users including hospitals, oncology clinics, and home healthcare settings.

The phesgo market consists of sales of complementary chemotherapy agents, diagnostic and monitoring tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.